19 December 2023
By 2023, Nacimbio holding has delivered nearly 300,000 vaccine doses for the prevention of measles, rubella, and mumps. To maintain a steady supply and minimize any risks of shortages, these vaccines will be promptly and continuously distributed to the public as soon as they are made available – as Ministry of Industry and Trade of Russia said.
“Nacimbio JSC, as part of the execution of government contracts with the Federal Institution “FCPiLO” of the Ministry of Health of Russia, in 2023 supplied immunobiological drugs to the constituent entities of the Russian Federation: almost 300 thousand doses of vaccine for the prevention of measles, rubella and mumps have already been supplied. <…> In order to prevent defects, the shipment of vaccines will be carried out on an ongoing basis as they are released into civilian circulation with an even distribution across the constituent entities of the Russian Federation,” the ministry said.
They have also highlighted that by December 22nd, an additional 344,000 doses of the comprehensive vaccine are anticipated to be delivered, along with 38,000 doses of the mumps prevention vaccine and 54,000 doses of the measles and mumps prevention vaccine. “The remaining volume of vaccines will be shipped to the regions by the end of the first quarter of 2024,” the Ministry of Industry and Trade added.
Print06 September 2024
NovaMedica expands its line of products for the treatment of Alzheimer’s disease
22 August 2024
Children visited the NovaMedica Innotech pharmaceutical manufacturing facility
14 June 2024
From January to August 2024, Russia’s medicinal product production totaled 530.7 billion rubles
27 September 2024
The government has expanded medicine sales in villages without pharmacies
27 September 2024
FDA issues draft guidance to help industry conduct global cancer clinical trials
26 September 2024
Optimizing Patient Support Through Effective Information Governance: Balancing Risks and Rewards
26 September 2024